Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Appili Therapeutics Inc T.APLI

Alternate Symbol(s):  APLIF

Healthcare
Appili Therapeutics Inc. is a Canada-based biopharmaceutical company. The Company is advancing a diverse range of anti-infectives, including a vaccine candidate to eliminate a serious biological weapon threat, a topical antiparasitic for the treatment of a disfiguring disease, and a novel easy to use, liquid oral formulation targeting parasitic and anaerobic infections. The Company’s anti... see more

Recent & Breaking News (TSX:APLI)

Appili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2023

Business Wire February 14, 2023

Appili Therapeutics Announces that FDA accepts the ATI-1501 NDA

Business Wire February 8, 2023

Appili Therapeutics Appoints Dr. Carl Gelhaus and Arthur Baran to support the ATI-1701 Biodefense Vaccine Program

Business Wire January 17, 2023

Appili Therapeutics Announces Notice of Allowance from the U.S. Patent and Trademark Office for ATI-1501 Liquid Oral Reformulation of Metronidazole

Business Wire January 13, 2023

Appili Therapeutics ATI-1701 Biodefense Vaccine Secures ~US$14 Million of Funding from the U.S. Department of Defense in Partnership with the U.S. Air Force Academy

Business Wire November 14, 2022

Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2023

Business Wire November 10, 2022

Appili Therapeutics Announces Results of Annual and Special Meeting of Shareholders

Business Wire September 22, 2022

Appili Therapeutics Reports Financial and Operational Results for First Quarter of Fiscal Year 2023

Business Wire August 12, 2022

Appili Therapeutics to Present at WorldLeish7 Conference in Cartagena, Columbia

Business Wire August 2, 2022

Appili Therapeutics Reports Fiscal Year 2022 Financial and Operational Results

Business Wire June 29, 2022

Appili Therapeutics Announces Closing of Public Offering of $4,500,000

Business Wire May 26, 2022

IIROC Trade Resumption - APLI

Canada NewsWire May 18, 2022

Appili Therapeutics Announces Pricing of Overnight Marketed Equity Offering

Business Wire May 18, 2022

IIROC Trading Halt - APLI

Canada NewsWire May 17, 2022

Appili Therapeutics Announces Overnight Marketed Equity Offering

Business Wire May 17, 2022

Appili Therapeutics to Present at the 2022 Bloom Burton & Co. Healthcare Investor Conference

Business Wire April 27, 2022

Appili Therapeutics Announces New Late-Stage Clinical Program ATI-1801 to Treat Cutaneous Leishmaniasis

Business Wire April 13, 2022

Appili Therapeutics (TSX:APLI) secures US$3.6M loan, license and distribution agreement with Long Zone Holdings

Caroline Egan  March 29, 2022

Appili Therapeutics Announces Non-Convertible Secured Loan of US$3.6 Million and License and Distribution Agreement with Long Zone Holdings

Business Wire March 29, 2022

Appili Therapeutics Announces Over US$10 Million in New Funding from US Department of Defense for Biodefense Vaccine Candidate ATI-1701

Business Wire February 28, 2022